Member Info for Robin292

Firing : Morning. We have 2 options: 1. CAM board (usually reserved for my LSE ladies)..mostly attractive ones OR 2. SEN board as it's the closest to XEN Do we need a vote on this. I'll let the veteran posters decide.

Here we go again. Board full of playboys, millionaires and great thinkers. 3 minutes from RNS..3 minutes from a German cruiser with full leather and AMG alloys.

Sold a new shape Saab 9-3 tid 150bhp to buy this..last thing I want is an Astra. Dutchess promised me a Mercedes budget.

Buys coming in now.

Will monitor this afternoon..expecting more surely. Love to know who bought.

Well, no other reason to be in court is there? If positive news, we should see some action before RNS.

Morning Lordus, looking positive. We should have RNS very soon.

Bit of volume this am. Circa 110k buys at 5.94 ish.

Aha..this means no message board for us on the LSE surely? 2 options : we choose a new one (unused) or I'm happy to contribute a " lady board" which is usually reserved for my ladies. Remember when we went from the KDD board to the FDI one with intros?

Rather have a Cactus tree for lunch than Egbertha. No offence to her but eating Cadbury's Dairy Milk during Yoga is not a " get fit quick " plan that works.

so we should see some action Monday am, all being well. Interesting.

"whatcha talking about Willis?" What you thinking..I'm starving.

Ok..I refuse to eat until we get a buy. I'm on a hunger strike but not like the IRA ones where they made a mess at the same time.

Obviously not. If I wanted bad news and abusive texts..I'd contact my ex.

Can someone text me on 0898696969 when we have a purchase pls..saves me checking every 20 mins.

Still in the TA's firing?

Roxy: if I had insurance for my ebay Samsung laptop..I'd definitely request one. Your last one needed sun glasses for the reader. ps. you blew a £450 Toshiba Lordy: MKD still has FDI's..I'm a re-enterer.

o/t no use CEO ringing up Frankie S..he won't have a clue. Infact he'd say : " Diamonds? What diamonds? "

I'm thinking a string of positive news as we launch into the hands of our overweight cousins. Got in at 6.3 yesterday (buy order)..this Saab money better turn into Merc money. So once listed in USA..we'll be watching the live sp but 15 mins late and a 2pm ish start for us I guess. * FDI on the up with our KDD free money I see.

Xenetic Biosciences Phase II Dosing Commenced RNS Number : 1476R Xenetic Biosciences PLC 23 October 2013  Xenetic Biosciences PLC ('Xenetic' or the 'Company') Phase II Clinical Trial for ErepoXen® commences with Dosing of First Patient Xenetic Biosciences PLC (LSE: XEN), a bio-pharmaceutical company specialising in the development of high-value differentiated biologics, vaccines and novel cancer drugs, announces that as part of its western Phase II study of ErepoXen®, its Contract Research Organisation ("CRO") Novotech, has dosed the first patient. ErepoXen® is a novel therapy for the treatment of anaemia in End Stage Renal Disease patients. Anaemia in subjects with chronic kidney disease is often accompanied by a decreased quality of life and an increased need for red blood cell transfusions. The dominant treatment for this condition is recombinant human erythropoietin ('rHuEPO') replacement therapy with an erythropoiesis-stimulating agent ('ESA'), which has been associated with an improved quality of life and fewer Red Blood Cell ('RBC') transfusions. ErepoXen® is Xenetic's polysialylated erythropoietin (PSA-EPO) candidate for the treatment of patients with chronic anaemia. The product contains the identical amino acid sequence of isolated natural human EPO and the polysialic acid used is a natural hydrophilic polymer derived from the cGMP fermentation of E. Coli strain K1. Polysialylation of EPO helps in reducing the required frequency of dosing compared to existing ESAs due to its longer in-vivo half-life. The primary endpoint of this Phase II, open-label, multi-centre and sequential dose finding trial is to assess the efficacy and safety of multiple doses of polysialylated recombinant human erythropoietin (PSA-EPO) in chronic kidney disease ('CKD') subjects who are not receiving dialysis nor receiving erythropoiesis stimulating agents (ESAs). The trial is being conducted in compliance with Australian and New Zealand regulations under a clinical protocol that includes eight centres in Australia and an additional two in New Zealand. The trial is expected to be active for up to 14 months with up to 72 males and females over the age of 18 enrolled. The first report on this trial is expected during H2-2014. The treatment has been formulated using the Company's patented PSA and PSA-EPO technologies. If successful the proprietary PSA-EPO treatment will address an anaemia market currently estimated at US$7.2 Billion. M. Scott Maguire, CEO of Xenetic, commented: "This is a pivotal moment for the Company as this first western clinical trial gets under way on our lead biologic product candidate, ErepoXen®. Based upn the excellent work and positive clinical trial results already achieved in India by our co-development partner Serum Institute of India, the Xenetic Board is confident of achieving a positive outcome to this latest